Friday, September 30, 2016

Aricept


See also: Generic Aricept ODT


Aricept is a brand name of donepezil, approved by the FDA in the following formulation(s):


ARICEPT (donepezil hydrochloride - tablet; oral)



  • Manufacturer: EISAI INC

    Approval date: November 25, 1996

    Strength(s): 10MG [RLD][AB], 5MG [AB]


  • Manufacturer: EISAI INC

    Approval date: July 23, 2010

    Strength(s): 23MG [RLD]

Has a generic version of Aricept been approved?


A generic version of Aricept has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Aricept and have been approved by the FDA:


donepezil hydrochloride tablet; oral



  • Manufacturer: ACCORD HLTHCARE

    Approval date: August 29, 2011

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: ACTAVIS PHARMA

    Approval date: May 31, 2011

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: APOTEX

    Approval date: June 2, 2011

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: AUROBINDO

    Approval date: May 31, 2011

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: CIPLA LTD

    Approval date: May 31, 2011

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: DR REDDYS LABS LTD

    Approval date: May 31, 2011

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: HIKMA PHARMS

    Approval date: May 31, 2011

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: HUAHAI US INC

    Approval date: May 31, 2011

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: JUBILANT LIFE

    Approval date: May 31, 2011

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: MATRIX LABS LTD

    Approval date: May 31, 2011

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: PLIVA HRVATSKA DOO

    Approval date: May 31, 2011

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: RANBAXY

    Approval date: November 26, 2010

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: ROXANE

    Approval date: May 31, 2011

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: SANDOZ

    Approval date: May 31, 2011

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: SUN PHARM INDS

    Approval date: May 31, 2011

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: TEVA

    Approval date: May 31, 2011

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: TORRENT PHARMS

    Approval date: May 31, 2011

    Strength(s): 10MG [AB], 5MG [AB]


  • Manufacturer: WOCKHARDT

    Approval date: May 31, 2011

    Strength(s): 10MG [AB], 5MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aricept. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Polymorphs of donepezil hydrochloride and process for production
    Patent 5,985,864
    Issued: November 16, 1999
    Inventor(s): Imai; Akio & Watanabe; Hideaki & Kajima; Takashi & Ishihama; Yasushi & Ohtsuka; Akiyo & Tanaka; Tomohide & Narabu; Yukio
    Assignee(s): Eisai Co., Ltd.
    Donepezil hydrochloride, 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride, is provided here in the form of four polymorphs which are stable against heat and humidity in the pharmaceutical use. They can be industrially produced. They are specified by peaks in X-ray powder diffraction pattern and absorption peaks in infrared absorption spectra in potassium bromide.
    Patent expiration dates:

    • December 30, 2016




  • Polymorphs of donepezil hydrochloride and process for production
    Patent 6,140,321
    Issued: October 31, 2000
    Inventor(s): Imai; Akio & Watanabe; Hideaki & Kajima; Takashi & Ishihama; Yasushi & Ohtsuka; Akiyo & Tanaka; Tomohide
    Assignee(s): Eisai Co., Ltd.
    Donepezil hydrochloride, 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride, is provided here in the form of four polymorphs which are stable against heat and humidity in the pharmaceutical use. They can be industrially produced. They are specified by peaks in X-ray powder diffraction pattern and absorption peaks in infrared absorption spectra in potassium bromide.
    Patent expiration dates:

    • December 30, 2016




  • Donepezil polycrystals and process for producing the same
    Patent 6,245,911
    Issued: June 12, 2001
    Inventor(s): Imai; Akio & Ichinohe; Toshiyuki & Endo; Takashi & Tsurugi; Tomio & Uemura; Makoto
    Assignee(s): Eisai Co., Ltd.
    The present invention provides novel polymorphic crystals (A) to (C) having excellent handling properties and an extremely low content of residual solvent of donepezil used as a precursor for production of donepezil hydrochloride having an excellent action as a medicament, and an industrial process for producing the same. Further, the novel polymorphic crystals (A) to (C) according to the present invention are characterized by the powder X-ray diffraction pattern and/or IR absorption peaks of donepezil represented by the following formula: ##STR1##
    Patent expiration dates:

    • December 1, 2018




  • Stabilized composition comprising antidementia medicament
    Patent 6,372,760
    Issued: April 16, 2002
    Inventor(s): Akira; Kato & Tsutomu; Harada & Naokazu; Murahashi & Yukiko; Sugaya & Hidenobu; Ando
    Assignee(s): Eisai Co., Ltd.
    The present invention provides a stable composition of an antidementia medicament. Specifically, it is a stabilized composition of an antidementia medicament comprising an antidementia medicament and an organic acid. As the organic acid, tosyllic acid, mesyllic acid, benzoic acid, salicylic acid, tartaric acid, citric acid and the like are particularly preferable.
    Patent expiration dates:

    • March 31, 2019
      ✓ 
      Sponsor has requested patent be delisted



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • July 23, 2013 - NEW PRODUCT

See also...

  • Aricept Consumer Information (Drugs.com)
  • Aricept Consumer Information (Wolters Kluwer)
  • Aricept Consumer Information (Cerner Multum)
  • Aricept Advanced Consumer Information (Micromedex)
  • Aricept AHFS DI Monographs (ASHP)
  • Donepezil Consumer Information (Wolters Kluwer)
  • Donepezil Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
  • Donepezil Consumer Information (Cerner Multum)
  • Donepezil Advanced Consumer Information (Micromedex)
  • Donepezil Hydrochloride AHFS DI Monographs (ASHP)

No comments:

Post a Comment